Trial Profile
Study of phase II, multicenter, open, assessing dasatinib in patients of acute myelogenous leukemia (AML) to core binding factors (CBF) resistant to conventional chemotherapy or molecular relapse.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2012
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DasaCBF
- 03 Jul 2012 New trial record